IPO Summary: Biotech Bonanza! IPO Window Remains Open for Hot Healthcare Names
Hemab Therapeutics (COAG): RA Capital Strikes Again, Hemab Rips Higher on Day One Hemab Therapeutics (COAG US) delivered one of the standout biotech debuts of 2026, combining strong deal dynamics with powerful aftermarket momentum. The company priced 16.75 million shares—upsized again from 15.0 million—at $18.00, the high end of the range, signaling robust institutional demand heading[…]
